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Human immunodeficiency virus type 1 (HIV-1) is frequently attenuated after long-term culture in vitro. The
attenuation process probably involves mutations of functions required for replication and pathogenicity in
vivo. Analysis of attenuated HIV-1 for replication and pathogenicity in vivo will help to define these functions.
In this study, we examined the pathogenicity of an attenuated HIV-1 isolate in a laboratory worker accidentally
exposed to a laboratory-adapted HIV-1 isolate. Using heterochimeric SCID-hu Thy/Liv mice as an in vivo mod-
el, we previously defined HIV-1 env determinants (HXB/LW) that reverted to replicate in vivo (L. Su, H. Kane-
shima, M. L. Bonyhadi, R. Lee, J. Auten, A. Wolf, B. Du, L. Rabin, B. H. Hahn, E. Terwilliger, and J. M.
McCune, Virology 227:46–52, 1997). Here we further demonstrate that HIV-1 replication in vivo can be sep-
arated from its pathogenic activity, in that the HXB/LW virus replicated to high levels in SCID-hu Thy/Liv
mice, with no significant thymocyte depletion. Restoration of the nef gene in the recombinant HXB/LW genome
restored its pathogenic activity, with no significant effect on HIV-1 replication in the thymus. Our results
suggest that in vitro-attenuated HIV-1 lacks determinants for pathogenicity as well as for replication in vivo.
Our data indicate that (i) the replication defect can be recovered in vivo by mutations in the env gene, without
an associated pathogenic phenotype, and (ii) nef can function in the HXB/LW clone as a pathogenic factor that
does not enhance HIV-1 replication in the thymus. Furthermore, the HXB/LW virus may be used to study
mechanisms of HIV-1 nef-mediated pathogenesis in vivo.
Human immunodeficiency virus type 1 (HIV-1) diseases
(AIDS) are associated with high levels of HIV-1 viremia and
depletion of CD41 T lymphocytes. In vivo, HIV-1 can infect
diverse cell types, including CD41 T cells, macrophages, den-
dritic cells, Langerhans cells, and hematopoietic progenitor
cells (13, 24, 30, 39, 42). However, the HIV-1 isolates used in
many studies have been expanded and maintained in immor-
talized human T-cell lines. The different selective pressures in
vitro have led to the generation of variants with attenuated
replication and pathogenicity in vivo (38). Many laboratory-
adapted isolates of HIV-1 show defects in the functions of
some genes, such as env, vpr, vpu, and nef (38). A good example
of such adaptation in vitro is Lai/IIIB (human T-cell lympho-
tropic virus strain IIIB) (6). Initially derived from a human
patient blood sample and cultured in MT2/B cells, Lai/IIIB
stock was prepared by infecting the human leukemia T-cell line
H9 with infected MT2/B-cell supernatant. Subsequent analyses
of the genome from the Lai/IIIB isolate showed that multiple
changes accumulated during expansion in vitro (38). For ex-
ample, the HXB2 genome cloned from Lai/IIIB carries muta-
tions that lead to premature termination of three of the nine
open reading frames (ORFs): vpr, vpu, and nef. Many other
subtle mutations also may have accumulated. These mutations
do not usually affect HIV-1 replication in vitro under specific
culture conditions, although some of them may enhance viral
replication in certain cell lines. However, it remains unclear
which mutations contribute to attenuated HIV-1 replication
and pathogenesis in vivo.
It has been difficult to analyze HIV-1 functions specifically
involved in pathogenicity. Mutations in putative pathogenic
factors such as nef or env in simian immunodeficiency virus
(SIV) or HIV-1 have led to reduced viremia in vivo (1, 14, 34,
40). Thus, the reduced pathology may be due to a reduced viral
load in vivo. Such pathogenic factors are therefore also repli-
cation factors. Transgenic mouse models in which nef is ex-
pressed constitutively in thymocytes and CD41 T and macro-
phage cells lead to CD41 T-cell depletion and other AIDS-like
symptoms, suggesting that nef may be a principal pathogenic
factor (15). However, problems arise with transgenic mouse
models during attempts to correlate nef expression with virus-
mediated pathogenicity. First, the level and time of transgenic
nef expression are very different from those in HIV-1 infection
in humans. Second, murine host cells may respond differently
to HIV-1 nef proteins. Therefore, whether nef is a factor for
replication and/or pathogenicity in vivo is still not clear.
Comparison of HIV-1 isolates attenuated in vitro with
pathogenic revertants in vivo will help to identify viral deter-
minants important for replication and pathogenesis in vivo.
One example of a factor involved in pathogenicity is found in
SHIV (SIV-HIV env chimeric genome) adapted in monkeys.
SHIV variants with enhanced replication and pathogenicity
have been isolated from monkeys infected with SHIV recom-
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binant viruses (19). Mutations in HIV env genes have been
identified which contribute to enhanced replication in mon-
keys. Interestingly, env determinants have also been defined
that specifically contribute to CD41 T-cell depletion (i.e.,
pathogenicity) but not replication in monkeys (12). Therefore,
unique env determinants have intrinsic pathogenic activity in
monkeys.
The Lai/IIIB isolate and its associated infectious molecular
clones (e.g., HXB2) were found to infect T-cell lines such as
H9 as well as peripheral blood mononuclear cells (PBMCs) in
vitro but to be replication defective in vivo (14, 34, 40). When
a laboratory worker was accidentally infected by Lai/IIIB, in-
fectious virus was isolated from plasma by infection of primary
PBMCs but not by infection of T-cell lines (22, 43). We have
previously used SCID-hu Thy/Liv mice as an in vivo model (29,
31) to study the replication of HXB2 and of HXB2 recombi-
nant viruses containing HIV-1 fragments isolated from the
infected laboratory worker (40). Like Lai/IIIB, HXB2 failed to
replicate in the Thy/Liv organ (4, 40). Replacement of an
HXB2 subgenomic fragment containing the env ORF with the
corresponding fragment from the laboratory worker isolate
(LW12.3) generated a recombinant virus (HXB/LW) which
replicated in SCID-hu Thy/Liv mice and in the human fetal
thymus organ culture (HF-TOC) model (23, 40). The specific
in vivo replication determinants were mapped to the region
from V1 to V3 of the HXB/LW env gene (40). Therefore, the
attenuated Lai/IIIB isolate acquired in vivo replication activity
by mutational reversion of the env gene in the infected labo-
ratory worker.
We used the SCID-hu Thy/Liv model to study the patho-
genic activity of HXB/LW. HXB/LW replicated to high levels
in the SCID-hu Thy/Liv mouse and HF-TOC models. How-
ever, the pathogenic activity of HXB/LW was significantly re-
duced. Restoration of the defective nef ORF in HXB/LW
resulted in enhanced viral pathogenicity, with no significant
effect on viral replication, in both the SCID-hu Thy/Liv mouse
and the HF-TOC models. Thus, we demonstrated in this study
that it was possible to separate the replication activity of a
recombinant HIV-1 clone from its pathogenicity in vivo and
that an intact nef ORF was able to serve exclusively as an
HIV-1 pathogenic factor in the replication-competent recom-
binant virus.
FIG. 1. Similar replication kinetics of HXB/LW and NL4–3 in SCID-hu Thy/Liv mouse and HF-TOC model systems. (A) Replication of
HXB/LW and NL4–3 in SCID-hu Thy/Liv mice. Levels of p24 capsid protein associated with 106 cells are shown on the y axis. Each column
represents the average values for each virus (numbers in parentheses are numbers of animals), along with standard error bars. (B) Replication of
HXB/LW and NL4–3 in HF-TOC. Thymus fragments were infected with equivalent infectious units, and thymocytes were harvested at various
times postinfection. Levels of p24 capsid protein associated with 106 cells are shown on the y axis. Data represent the average values at the indicated
times (numbers in parentheses are numbers of donors), along with standard error bars. (C) Quantitation of proviral DNA. Human thymocytes from
SCID-hu Thy/Liv mice infected with NL4–3 (two SCID-hu Thy/Liv mice; panels NLa and NLb), HXB/LW (three SCID-hu Thy/Liv mice; panels
LWa to LWc), or HXB2 (panel HB) were assayed by 10-fold dilution of infected cells into uninfected human cells. Lanes 1, 10,000 sample cells;
lanes 2, 1,000 sample cells plus 9,000 normal human cells; lanes 3, 100 sample cells plus 9,900 normal human cells. ACH2 cells (one HIV-1 genome
per cell) were used as standard controls (lane 4, 10 ACH2 cells plus 9,990 normal human cells; lane 5, 1 ACH2 cell plus 9,999 normal human cells;
lane 6, 10,000 normal human cells). b-Globin primers were used as internal controls.
TABLE 1. Summary of HIV-1 isolates and clones
HIV-1 PBMCa Thy-Repb
Presence (1) or absence
(2) of the following
HIV-1 gene:
nef vpr vpu
Lai/IIIB 1 2 2 2 2
HXB2 1 2 2 2 2
NL4-3 1 1 1 1 1
HXB/LW 1 1 2 2 1
a Ability to replicate in activated human PBMCs.
b Ability to replicate in human thymus.
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FIG. 2. Reduced pathogenicity of HXB/LW in human thymus. (A) Replication and pathogenic activities of NL4–3, HXB2, and HXB2/LW in
SCID-hu Thy/Liv mice. SCID-hu Thy/Liv mice were injected with equivalent infectious units of each virus, and thymocytes were analyzed at 4
weeks postinfection. Levels of cell-associated p24 antigen in 106 thymocytes were measured. (B) Comparison of CD41 thymocyte depletion in
SCID-hu Thy/Liv mice infected with HXB/LW or NL4–3. Thymocytes from the infected SCID-hu Thy/Liv organs shown in Fig. 1A were analyzed
by FACS for CD4 and CD8. The total percentages of CD41 thymocytes (CD41 CD82 and CD41 CD81) are shown on the y axis. The percentage
of total CD41 cells in mock-infected animals at each time point in each experiment was set to 100%. The results shown are the average values,
along with standard error bars. (C) Immunohistochemical staining of NL4–3- and HXB/LW-infected SCID-hu Thy/Liv organs. Frozen sections of
NL4–3-infected (upper panels) and HXB/LW-infected (lower panels) SCID-hu Thy/Liv organs (6 weeks postinfection [wpi]) were stained with
human anti-HIV serum and hematoxylin-eosin to detect HIV antigens and thymocytes, respectively. Magnifications: 310 for left panels and 360
for right panels. (D) Comparison of CD41 thymocyte depletion in HF-TOC infected with HXB/LW or NL4–3. Thymocytes isolated from the
infected HF-TOC fragments shown in Fig. 1B were analyzed by FACS for CD4 and CD8. The total percentages of CD41 thymocytes (CD41 CD82
and CD41 CD81) are shown on the y axis. The percentage of total CD41 cells in mock-infected tissues at each time point in each experiment was
set to 100%. The results shown are the average values, along with standard error bars.
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MATERIALS AND METHODS
Construction of recombinant HIV-1 genomes. HXB2 genomic DNA was di-
gested with SalI and BamHI to remove a 2.7-kb fragment, and the corresponding
fragment from LW12.3 was ligated into the provirus DNA to generate the
HXB/LW provirus. The mutations in vpr and nef are still present in the HXB/LW
genome (22, 40).
Construction of HXB/LW-nef1 (HXB/LWn1) was carried out by first sub-
cloning the 39 half of the HXB/LW provirus into pBluescript (pBS) SK(1)
(Invitrogen). The HXB/LW nef gene was then repaired by a recombination PCR
(RPCR) site-directed mutagenesis method described previously (11). First, the
39 half of the HXB/LW proviral genome was amplified by PCR with primer HC5
(GGGTGTCGACATAGCAGAATAGGC), which includes the SalI site in the
vpr gene, and primer HIV39-X (CGGCTCTAGAGATTTTCCACACTGACTA
AAAGG), which anneals to the 39 terminus of the genome and contains a
39-terminal XbaI site. This genomic fragment was subcloned into pBS. The
resulting pBS.HIV-LW.Sal/Xba plasmid (pBS-39HX/LW) was then used as tem-
plate DNA for RPCR mutagenesis as previously described in detail (11). Briefly,
two pairs of overlapping primers were used in RPCR mutagenesis. The mu-
tagenizing primer pair bound to overlapping regions of the HXB/LW nef gene.
The primers (forward, 59-CCCTGATTGGCAGAACTACACACC-39; re-
verse, 59-GTAGTTCTGCCAATCAGGGAAGTAGCC-39) incorporated an
AT-GC base change (underlined residues) which repaired the premature stop
codon in the HXB/LW nef gene. The nonmutagenizing primer pair bound to
overlapping regions of the pBS Ampr gene (59-GATGTAACCCACTCGTGCA
CCCAACTGAT-39; 59-GGGTGCAGCAGTGGGTTACATC-39). One primer
from each pair was used in two separate PCRs, each of which amplified about
half of the plasmid template and incorporated the base change from the mu-
tagenizing primers. The two sets of reaction products were pooled, cleaned, and
transformed directly into library-competent Escherichia coli DH5a cells (Gibco-
BRL). The mutagenized plasmid was then generated by in vivo recombination
between the overlapping ends of the PCR products (44).
Two clones were sequenced; both carried the repaired nef gene. One of these
was used to generate a recombinant proviral genome by subcloning the 39
fragments back into the HXB/LW genome. A low-mutation-rate polymerase with
proofreading capability (Boehringer Mannheim Biochemicals) was used in all
PCRs. However, as additional confirmation that the DNA amplification did not
interfere with either the replication or the pathogenicity of the mutant, a non-
mutagenized control plasmid was generated in a parallel reaction. The nef1
mutant pBS-39LWn1 and the nef2 control pBS-39LWn2 plasmids were both
digested with SalI and XbaI and gel purified. HXB/LW proviral plasmid DNA
was digested with SalI and XhoI and gel purified. The digested proviral plasmid
DNA was partially ligated at the SalI site with either the 39-LWn1 or the
39-LWn2 insert. A293T cells were transfected with the partially ligated DNA
using Effectine reagent (Qiagen, Inc.), and the viral supernatant was collected
after 48 h and amplified in phytohemagglutinin (PHA)-activated PBMCs. The
HXB/LWn1 proviral DNA was used directly as a template for sequencing with
primers from either side of the insert based on sequences from HXB2. Se-
quences were confirmed from both strands.
HIV-1 replication in PBMCs and viral supernatant production. Proviral DNA
(0.8 mg) was transfected into A293T cells, and supernatants were used to infect
PHA-activated PBMCs as described previously (23, 39). Supernatants were col-
lected and analyzed by a multinuclear activation of a galactosidase indicator
FIG. 3. Repaired nef gene did not alter HXB/LW replication kinetics. (A) The expression of nef in A293T cells transfected with proviruses
encoding HXB2, HXB/LWn2, and HXB/LWn1 was detected by Western blot analysis. The same blot was probed with an antitubulin MAb to
monitor total protein levels. (B) The expression of nef in H9 T cells infected with HXB2, HXB/LWn2, and HXB/LWn1 was detected by Western
blot analysis. NL4–3-infected H9 cells were included as positive controls. The same blot was probed with an antitubulin MAb to monitor total
protein levels. (C) Similar levels of HXB/LWn1, HXB/LWn2, and NL4–3 replication in SCID-hu Thy/Liv mice. SCID-hu Thy/Liv organs were
infected with equivalent infectious units, and thymocytes were harvested at various times. Levels of p24 capsid protein associated with 106 cells are
shown on the y axis. Each column represents the average of three independent experiments (numbers in parentheses are numbers of animals),
along with calculated standard error bars. (D) Similar levels of HXB/LWn1, HXB/LWn2, and NL4–3 replication in HF-TOC. Fetal thymus
fragments were infected with equivalent infectious units, and thymocytes were harvested at various times. Levels of p24 capsid protein associated
with 106 cells are shown on the y axis. Values at each time point represent averages from four independent experiments (numbers in parentheses
are numbers of donors), along with calculated standard error bars.
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(MAGI) assay performed as previously described using U373-MAGI-
CXCR4CEM glioblastoma cells (41). Supernatants with titers of greater than 5 3
104 infectious units (IU)/ml were stored as viral stocks for infection.
Western blot analysis of nef expression. Western blot analysis was performed
with total cell extracts from transfected A293T cells or infected H9 T cells as
described previously (23). The anti-nef polyclonal antibody (kindly provided by
R. Swanstrom, University of North Carolina, Chapel Hill) was used to detect the
nef protein. NL4–3 virus-infected H9 cells were used as positive controls. An
antitubulin monoclonal antibody (MAb) was used to monitor protein levels.
Infection of SCID-hu Thy/Liv mice or HF-TOC. Animal transplantation pro-
cedures for SCID-hu Thy/Liv construction have been described elsewhere (32).
Infection of SCID-Thy/Liv mice was performed as previously described (39).
Briefly, SCID-hu Thy/Liv mice were infected with supernatants collected from
PHA-activated PBMCs containing no HIV-1 (mock) or 4 3 104 IU of HIV-1/ml.
Fifty microliters (;2,000 IU) was injected into each thymus graft. Biopsy spec-
imens were obtained from Thy/Liv organs at various times, and thymocytes were
analyzed for p24 and proviral DNA. Thymocyte subsets were analyzed with a
fluorescence-activated cell sorter (FACS) as described below.
The HF-TOC procedures were modified slightly from those described previ-
ously (4). Briefly, human fetal thymi (19 to 24 gestational weeks) were dissected
into ;2-mm3 fragments containing at least three to five intact thymic lobules
under a dissecting microscope. These fragments were transferred onto sterile or-
gan culture membranes (Millipore) floating on medium (RPMI medium, 10%
fetal calf serum, 50 mg of streptomycin/ml, 50 U of penicillin G/ml, minimal
essential medium vitamin solution [Gibco-BRL], insulin-transferrin-sodium se-
lenite medium supplement [Sigma]) in six-well tissue culture plates. Equal
amounts of virus (;800 IU) in 20 ml of supernatant from infected PHA-activated
PBMCs or 20 ml of control supernatant from mock-infected PHA-activated
PBMCs was added to each fragment. The fragments were then cultured at 37°C
in 5% CO2 for 7 to 12 days with daily changes of culture medium. Thymocytes
were teased out of the fragments and analyzed as described above.
Viral replication assays. p24 production (picograms/106 thymocytes) was mea-
sured using a Vironostica p24 enzyme-linked immunosorbent assay (ELISA) kit
(Organon Teknika Corp., Durham, N.C.) and cell lysate in phosphate-buffered
saline (PBS)–1% Triton X-100. Semiquantitative DNA PCR analysis was per-
formed as described previously (23, 39). Briefly, human thymocytes from HIV-1-
or mock-infected Thy/Liv grafts were assayed by 10-fold dilution of infected cells
into uninfected human cells. Genomic DNA was prepared from the mixed cells.
ACH2 cells (one HIV-1 genome per cell) were used as standard controls.
Immunohistochemistry. At 6 weeks postinfection, SCID-hu Thy/Liv organs
were fixed in PBS–4% paraformaldehyde, frozen, and sectioned. They were then
stained with human anti-HIV-1 serum as described previously (3).
Flow cytometric analyses. Thymocytes isolated from SCID-hu Thy/Liv organs
or HF-TOC fragments were stained with phycoerythrin-CD4 and tricolor-CD8
(Caltag) in PBS–2% fetal bovine serum, washed, and resuspended in PBS–1%
formaldehyde as previously described (23, 39).
FIG. 4. Repaired nef gene enhanced pathogenesis in HXB/LW-
infected thymus. (A) Similar levels of thymocyte depletion in HXB/
LWn1- and NL4–3-infected SCID-hu Thy/Liv mice. SCID-hu Thy/Liv
mice were injected with equivalent infectious units of virus, and
thymocytes were harvested at 4 weeks postinfection and analyzed by
FACS. The thymocyte subpopulations were expressed as a percentage
of the events in the live gate. The levels of p24 capsid protein associ-
ated with 106 thymocytes in each SCID-hu Thy/Liv mouse were as
follows: LWn1, 490 ng; LWn2 (HXB/LW), 670 ng; and NL4–3, 67 ng.
(B) Pathogenesis kinetics in SCID-hu Thy/Liv mice infected with
HXB/LWn1, HXB/LWn2, and NL4–3. Thymocytes from the infected
SCID-hu Thy/Liv organs shown in Fig. 3C were analyzed by FACS at
the times shown on the x axis. The total percentage of CD41 thymo-
cytes relative to that in mock infections is shown on the y axis. The
percentage of total CD41 cells in mock-infected animals at each time
in each experiment was set to 100%. The results shown are the average
values, along with standard error bars. (C) Pathogenesis kinetics in
HF-TOC infected with HXB/LWn1, HXB/LWn2, and NL4–3. Thy-
mocytes from the infected HF-TOC fragments shown in Fig. 3D were
analyzed by FACS at the times shown on the x axis. The total percent-
age of CD41 thymocytes relative to that in mock infections is shown on
the y axis. The percentage of total CD41 cells in mock-infected animals
at each time in each experiment was set to 100%. The results shown
are the average values, along with standard error bars.
3920 DUUS ET AL. J. VIROL.
RESULTS
HXB/LW and NL4–3 infect the human thymus with similar
replication kinetics. NL4–3 and HXB/LW, as well as HXB2,
are derived from the Lai/IIIB isolate (Table 1). They all rep-
licate efficiently in PHA-activated PBMCs (40). HIV-1 repli-
cation in the SCID-hu Thy/Liv model was assessed by a p24
antigen ELISA and by DNA PCR analysis. As previously re-
ported (40), no significant HXB2 replication was detected up
to 6 weeks postinoculation. In contrast, challenge with the
recombinant HXB/LW virus was associated at 3 to 6 weeks
postinfection with high levels of viral replication, comparable
to that seen in NL4–3-infected Thy/Liv organs (Fig. 1A). Sim-
ilar results were obtained after infection with the same HIV-1
clones in the HF-TOC model (4, 40). Analysis of data from 18
independent experiments demonstrated that NL4–3 and HXB/
LW replicated to similar levels, with similar kinetics, in the
HF-TOC model (Fig. 1B). Quantitation of proviral DNA con-
firmed that about 10% of human thymocytes were infected
with HXB/LW, comparable to the infection levels seen with
NL4–3 (Fig. 1C) or primary isolates (39, 40).
HXB/LW replication was uncoupled from pathogenicity in
the human thymus. The HXB2 clone failed to replicate and
thus showed no detectable p24 capsid protein or thymocyte
depletion (Fig. 2A). NL4–3 infection of SCID-hu Thy/Liv or-
gans led to significant depletion (up to 90% of total CD41
thymocytes relative to the results obtained for mock-infected
Thy/Liv organs) of CD41 thymocytes at 3 to 8 weeks postin-
fection (Fig. 2A and B). In contrast, HXB/LW, with a level of
replication similar to that of NL4–3, showed no significant
depletion of thymocytes at up to 6 weeks postinfection (Fig. 2A
and B). Immunohistochemical detection of infected cells in
SCID-hu Thy/Liv organs infected with HXB/LW revealed
large numbers of thymocytes expressing HIV antigens within
well-defined cortex and medulla of intact thymic lobules (Fig.
2C, lower panels). As previously reported (3), NL4–3 infected
Thy/Liv organs were dramatically disrupted, and thymocytes
were depleted (Fig. 2C, upper panels).
Similar pathogenesis was observed with the HF-TOC system
(4). Only NL4–3-infected HF-TOC fragments showed signifi-
cant thymocyte depletion relative to that in mock-infected
fragments by 12 days postinfection (Fig. 2D).
The results of the replication and pathogenesis studies clear-
ly established a difference in the pathogenic activities of HXB/
LW and NL4–3. The replication activity of HXB/LW could be
separated from its pathogenic activity in both models of thymic
HIV-1 infection. This uncoupling of replication from pathoge-
nicity enabled us to use the HXB/LW virus to map replication-
independent genomic determinants of pathogenicity in vivo.
Restoration of the nef ORF in HXB/LW restored thymocyte
depletion in the human thymus. Like the LW12.3 clone iso-
lated from the infected laboratory worker, HXB/LW encoded
defective nef and vpr genes (Table 1) (40). Since it has been
reported that vpr is not required for the replication and patho-
genicity of HIV-1 in the SCID-hu Thy/Liv model (2, 18), we
tested whether nef could enhance the pathogenicity of HXB/
LW in the in vivo model. HXB/LW with a restored nef ORF
(HXB/LWn1) was generated by repairing the premature stop
codon in the HXB/LW nef gene (see Materials and Methods).
An unmutagenized control virus (HXB/LWn2) was simulta-
neously generated with similar procedures. The HXB/LWn2
control virus was phenotypically indistinguishable from HXB/
LW in T-cell lines, in the HF-TOC system, and in SCID-hu
Thy/Liv mice (data not shown). As expected, HXB/LWn1, but
not HXB2 or HXB/LWn2 (or HXB/LW), expressed a full-
length nef protein in both transfected A293T cells and infected
human T cells (Fig. 3A and B).
HXB/LWn1 and HXB/LWn2 showed similar replication
activities in SCID-hu Thy/Liv mice (Fig. 3C) and HF-TOC
(Fig. 3D). However, when pathogenic activity was analyzed in
these experiments, infection by HXB/LWn1 led to thymocyte
depletion at levels similar to those observed in NL4–3 infec-
tions (Fig. 4A), whereas HXB/LWn2-infected tissues showed
no significant thymocyte depletion. Kinetic analysis of thymo-
cyte depletion showed that HXB/LWn1 was similar to NL4–3
in pathogenicity, while HXB/LWn2 showed no significant
pathogenic activity until late times postinfection (Table 2 and
Fig. 4B and C). These results clearly demonstrated that repair-
ing the premature stop codon of the HXB/LWn2 nef gene was





Mean % of cells (SD) that were Mean ng of p24
(SD)/106 cellsLivea CD41 CD41 CD81 CD81
2 Mock 5 72.9 (10.8) 13.3 (3.7) 77.1 (5.7) 5.6 (1.0) 0
HXB/LWn2 6 76.2 (10.4) 12.2 (3.7) 67.0 (29.9) 6.6 (0.6) 1.3 (1.4)
HXB/LWn1 6 82.6 (4.6) 10.9 (1.5) 80.2 (2.3) 7.6 (1.5) 3.3 (2.7)
NL4-3 5 61.8 (11.3) 19.8 (11.0) 49.5 (11.8) 16.8 (5.7) 15.6 (14.1)
4 Mock 4 50.9 (14.5) 16.7 (7.5) 72.4 (8.0) 9.1 (1.2) 0
NXB/LWn2 5 45.0 (29.7) 15.6 (3.1) 55 (24.0) 22.1 (14.1) 210.9 (191.2)
HXB/LWn1 5 6.7 (5.0) 12 (10.8) 5.4 (5.7) 49.9 (17.7) 261.2 (313.2)
NL4-3 4 12.1 (4.2) 16.0 (8.6) 3.4 (1.8) 49 (15.1) 229.7 (240.5)
6 Mock 2 75.1 (3.9) 9.6 (1.8) 86.7 (2.1) 3.2 (0.4) 0
HXB/LWn2 2 19.2 (15.4) 22 (8.0) 57.3 (18.5) 14.3 (4.5) 37.1 (4.6)
HXB/LWn1 2 7.1 (0.4) 3.9 (4.1) 4.4 (1.2) 78.4 (2.0) 72.3 (23.2)
NL4-3 2 10.1 (3.6) 1.9 (1.0) 1.8 (0.5) 82.7 (6.9) 45.5 (12.3)
a Percentage of cells in live gate.
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sufficient to restore pathogenicity to this virus, without signif-
icantly altering its replication kinetics.
The replication of HXB/LW was genetically separable from
thymocyte depletion in SCID-hu Thy/Liv organs. To analyze
the relative replication and pathogenic activities of HXB/LW
(with or without a functional nef gene) and NL4–3, we plotted
the pathogenicity of each virus against its replication as de-
scribed previously (5). In comparison to NL4–3 standard
curves generated from 10 independent SCID-hu Thy/Liv ex-
periments (32 SCID-hu Thy/Liv mice infected with NL4–3)
(Fig. 5A) or 26 independent HF-TOC experiments (100 HF-
TOC fragments infected with NL4–3) (Fig. 5B), HXB/LWn2
showed significantly reduced pathogenic activity at similar viral
loads. In both model systems, all but two of the data points for
HXB/LWn2 remained above the NL4–3 standard curves (Fig.
5), demonstrating the reduced pathogenicity of this virus. In
contrast, HXB/LWn1 and NL4–3 from the same experiments
showed similar pathogenic activities in both the SCID-hu Thy/
Liv and the HF-TOC models (Fig. 5). The high R2 value (0.76)
for the HF-TOC NL4–3 standard indicates that the data points
fit with the nonlinear regression model (5). However, the low
value (R2 5 0.17) for the SCID-hu Thy/Liv NL4–3 standard
suggests that some data points did not fit the regression line as
well. This lack of fit was probably due to greater thymocyte
depletion at late times after infection with NL4–3 in Thy/Liv
organs (Fig. 4B) that led to reduced cell-associated p24 levels
(3, 39). The HF-TOC cultures did not reach the same level of
depletion (Fig. 4C).
Collectively, our results demonstrate that HXB/LWn2 has
the ability to replicate in vivo, but with significantly reduced
pathogenic activity. Furthermore, an intact nef ORF can re-
store its pathogenic activity, with no significant effect on its
replication in the thymus.
DISCUSSION
From a laboratory worker accidentally exposed to an atten-
uated HIV-1 isolate, viruses have been recovered that have
reverted to replicate in vivo (40, 43). Using SCID-hu Thy/Liv
mice as an in vivo model for HIV-1 replication and pathogen-
esis, we showed that the replication activity of a recombinant
HIV-1 clone derived from the laboratory worker isolate was
separable from its pathogenicity in vivo.
For other lentiviruses, single point mutations have been
shown to convert an attenuated virus to a pathogenic one in
vivo. However, pathogenic activity always has been correlated
with enhanced replication activity. For example, lower viral
loads were associated with reduced pathogenicity of SIV with
a nef deletion in monkeys (20) or of HIV-1 in SCID-hu Thy/Liv
mice (17). In a recent study of several CCR5-dependent HIV-1
isolates, Scoggins et al. also correlated replication efficiency in
SCID-hu Thy/Liv mice with pathogenicity (37). The present
study documented the first example of unique structural de-
terminants in HIV-1 that appear to enhance infectivity but not
pathogenicity in vivo.
Interestingly, the SalI-BamHI fragment of HXB2 that was
replaced by that of LW12.3 in HXB/LW also showed in vivo
defects in replication and pathogenicity in the SHIV genome
(26, 35). In one report, SHIV-HXB2c demonstrated greatly
reduced replication in infected monkeys compared with SHIV-
89.6 (a primary HIV-1 isolate), although both chimeric viruses
replicated efficiently in simian peripheral blood lymphocytes
in vitro (35). Both reports indicated that laboratory-adapted
HIV-1 isolates may have accumulated mutations in important
genes for in vivo replication and transmission. Even SHIV-89.6
showed reduced replication and pathogenicity in monkeys.
After several passages in vivo, SHIV variants with enhanced
replication and pathogenicity accumulated (19). Thus, multiple
determinants appear to be involved in both replication and
FIG. 5. Relative pathogenicity of HXB/LWn1, HXB/LWn2, and
NL4–3 correlated to the presence of an intact nef ORF. (A) Patho-
genic plot for SCID-hu Thy/Liv mice. p24 capsid protein levels (x axis)
were plotted against the total percentage of CD41 thymocytes relative
to that in mock infections (y axis) for the time points from 2 to 6 weeks
postinfection from the experiments shown in Fig. 3C. The NL4–3
standard regression curve was generated from 32 SCID-hu Thy/Liv
mice infected with the NL4–3 virus from 10 different experiments
(R2 5 0.17). Numbers of mice were as follows: HXB/LWn2, n 5 16
(F); HXB/LWn1, n 5 18 (M); NL4–3, n 5 14 (‚); and NL4–3
standard, n 5 32. (B) Pathogenicity plot for HF-TOC. p24 capsid
protein levels (x axis) were plotted against the total percentage of
CD41 thymocytes (y axis) for all time points from the HF-TOC ex-
periments shown in Fig. 3D. The NL4–3 standard regression curve was
generated from 100 HF-TOC assays of 26 different donor thymus
tissues infected with the NL4–3 virus (R2 5 0.79). Numbers of tissues
were as follows: HXB/LWn2, n 5 9 (F); HXB/LWn1, n 5 8 (M); and
NL4–3 standard, n 5 100.
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pathogenesis or uniquely in pathogenicity independent of rep-
lication.
Our results suggest that while the laboratory-attenuated Lai/
IIIB virus had recovered the ability to replicate in vivo through
passage in the infected laboratory worker, it had not regained
corresponding pathogenic activity. In the recombinant HXB/
LW, the nef gene can function as a pathogenic factor indepen-
dent of replication activity. We have shown that reversion of
the replication determinants in LW12.3 env was not sufficient
for pathogenicity in the human thymus. Restoration of the nef
gene was required for HIV-1 pathogenic activity in vivo. As
both env and nef are believed to be involved in replication as
well as pathogenicity, we propose that Lai/IIIB has been at-
tenuated by mutations in multiple genetic determinants re-
quired for replication and pathogenesis in vivo (Fig. 6). As the
virus was passaged in vivo, we propose that replication deter-
minants in env reverted to allow it to replicate more efficiently
in the infected laboratory worker. However, the attenuated
pathogenic determinants had not yet reverted in the LW12.3
isolate from which the recombinant HXB/LW was derived.
Additional pathogenic determinants are also implicated in the
HXB/LW virus because, at late times postinfection, HXB/LW-
infected Thy/Liv organs also showed low, but significant, levels
of thymocyte depletion (Fig. 2 and 4 and Table 2). The delayed
or attenuated pathogenic activity may be due to the attenuated
pathogenic LW12.3 env gene or to other HIV-1 pathogenic
factors.
Etemad-Moghadam et al. recently reported that env muta-
tions in in vivo-passaged SHIV were associated with increased
resistance to neutralizing antibody and that these mutations
exerted a negative effect on the pathogenic potential of the
virus in some cell lines (12). Consistent with this report, one of
the sequence changes in the env V3 loop common to HXB/LW
(40) and other isolates from the infected laboratory worker
(25, 43) is associated with escape from antibody neutralization
(10). Furthermore, this mutation interfered with the in vitro
pathogenicity of the virus (10). The CD41 T-cell count of the
infected laboratory worker has decreased in recent years, sug-
gesting the emergence of pathogenic revertants. Unfortu-
nately, no recent HIV-1 isolates from this patient are available
for analysis. However, based on our model (Fig. 6), we predict
that additional changes in genes such as env or nef resulting in
enhanced pathogenicity will be observed in later-stage labora-
tory worker isolates.
Many studies have demonstrated the importance of the nef
gene in the replication and pathogenicity of HIV-1. Alterations
and deletions in the nef gene have been associated with long-
term survivors (9, 21, 28, 36). nef has multiple effects on HIV-
1-infected cells: it down-regulates the CD4 receptor and major
histocompatibility complex class I molecules from the infected
cell surface and alters multiple T-cell signaling pathways (re-
viewed in references 8 and 33). These activities of nef have
been mapped to distinct functional domains of the protein (7,
16, 27). The HXB/LW virus provides a valuable system for de-
termining which functional domain of the nef protein is re-
quired specifically for in vivo HIV-1 pathogenicity in the hu-
man thymus. In addition, since the mechanism by which nef
exerts its pathogenic activity in vivo is largely unknown, the
HXB/LW virus may also be used to further examine mecha-
nisms of nef-mediated pathogenesis in vivo.
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